A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis

By Ruptanu Banerjee, research assistant, University of Massachusetts Amherst

The rapid expansion of RNA-based therapeutics has intensified the need for improved methods of mRNA synthesis that can deliver both high yield and high purity. Conventional in vitro transcription (IVT), typically driven by bacteriophage RNA polymerases such as T7, remains the dominant approach for producing mRNA. However, this process introduces several persistent challenges, including incomplete transcription, heterogeneous product populations, and the formation of double-stranded RNA (dsRNA) byproducts.

These impurities are not trivial. dsRNA contaminants can trigger innate immune responses, reduce translational efficiency, and complicate downstream purification. As RNA therapeutics scale toward broader clinical applications, these limitations have become increasingly significant.

Traditional workflows treat transcription and purification as separate steps. Following IVT, extensive downstream processing, such as chromatography or enzymatic cleanup, is required to isolate functional mRNA. These approaches are effective but add complexity, cost, and variability.

In response, recent work introduces a plasmid-based co-tethered transcription platform designed to address these challenges at the level of transcription itself. By rethinking how the transcription machinery is organized, this system aims to improve both the efficiency and fidelity of mRNA production.

Conceptual Framework Of Co-Tethered Transcription

At the core of this approach is the physical co-localization of key transcription components. Rather than allowing RNA polymerase, DNA template, and nascent RNA to interact freely in solution, the system brings these elements into close spatial proximity through a tethering strategy.

This design is based on the premise that transcription efficiency and product quality are influenced not only by enzyme kinetics but also by the spatial organization of the transcription environment. By constraining diffusion and stabilizing interactions between components, the co-tethered system seeks to:

• increase transcriptional efficiency
• reduce premature termination
• limit the formation of aberrant RNA species.

The plasmid-based platform enables the DNA template to remain associated with transcriptional machinery throughout the process. This sustained interaction contrasts with conventional IVT, where components diffuse freely and interact transiently.

Mechanistic Basis For Improved Performance

The advantages of co-tethered transcription emerge from several mechanistic effects.

First, the proximity of RNA polymerase to the DNA template increases the likelihood of reinitiation. In standard IVT, polymerase molecules must repeatedly locate and bind to template DNA in solution. By maintaining spatial proximity, the tethered system reduces this search process, effectively increasing transcriptional throughput.

Second, tethering may stabilize transcription complexes during elongation. RNA polymerases are prone to pausing or dissociation, particularly when synthesizing longer transcripts. A stabilized complex can improve processivity, resulting in longer and more complete RNA products.

Third, the system appears to reduce the formation of dsRNA byproducts. These contaminants often arise from template switching, self-priming, or interactions between complementary RNA strands. By constraining the transcription environment, the co-tethered approach may limit opportunities for such interactions to occur.

Together, these effects contribute to a more controlled transcription process that prioritizes full-length, functional RNA.

Reduction Of Double-Stranded RNA Impurities

One of the most notable outcomes of this platform is the reduction of dsRNA formation. In conventional IVT systems, dsRNA can arise through several mechanisms, including:

• antisense transcription
• self-complementarity within RNA sequences
• hybridization between RNA molecules.

These dsRNA species are particularly problematic in therapeutic contexts, where they can activate pattern recognition receptors such as toll-like receptors and RIG-I–like receptors.

The co-tethered system appears to mitigate these effects by limiting the interactions that give rise to dsRNA. By maintaining a more controlled transcriptional microenvironment, the system reduces the likelihood of unintended RNA-RNA hybridization.

This has important implications for downstream processing. Reduced dsRNA content may decrease the need for extensive purification, simplifying manufacturing workflows and improving overall yield.

Impact On mRNA Yield And Integrity

In addition to improving purity, the co-tethered platform demonstrates enhanced mRNA yield. This improvement is likely driven by a combination of increased initiation efficiency and improved elongation stability.

Higher yields are particularly valuable for applications requiring large quantities of mRNA, such as vaccines and gene therapies. In these contexts, even modest increases in efficiency can translate into significant reductions in cost and production time.

Equally important is the integrity of the resulting mRNA. Functional performance depends on the presence of full-length transcripts with correct sequence composition. Truncated or damaged RNA can reduce protein expression and introduce variability.

The co-tethered approach supports the production of structurally intact mRNA, as evidenced by downstream functional assays. These results suggest that improvements in transcriptional control directly translate into improved biological activity.

Comparison With Conventional IVT Workflows

Traditional IVT workflows rely on well-established enzymatic systems but are inherently limited by their open, diffusion-driven nature. While optimization strategies such as buffer composition, enzyme engineering, and template design have improved performance, they do not fundamentally alter the spatial dynamics of transcription.

In contrast, the co-tethered platform introduces a structural element to the process. By organizing transcription components in a defined configuration, it addresses inefficiencies that arise from stochastic interactions in solution.

This distinction highlights a broader shift in thinking. Rather than focusing solely on optimizing individual parameters, this approach considers the architecture of the system as a whole.

Integration With Existing Manufacturing Pipelines

For any new transcription method to be viable, it must integrate with existing manufacturing infrastructure. The plasmid-based nature of this system offers a potential advantage in this regard.

Plasmid DNA is already widely used in biomanufacturing, and its handling is well understood. Incorporating a co-tethered transcription strategy into existing workflows may therefore require fewer changes than entirely novel platforms.

However, several considerations remain. Scaling the tethered system to industrial volumes will require careful engineering to ensure consistent performance. Parameters such as component density, reaction conditions, and reproducibility must be validated.

Despite these challenges, the potential benefits — increased yield, reduced impurities, and simplified downstream processing — make this approach an attractive candidate for further development.

Broader Implications For RNA Manufacturing

The introduction of co-tethered transcription reflects a broader trend toward process-level innovation in RNA manufacturing.

Historically, advances in RNA therapeutics have been driven by improvements in sequence design, chemical modification, and delivery technologies. While these areas remain critical, manufacturing is increasingly recognized as a limiting factor.

As RNA molecules become longer, more complex, and more heavily modified, traditional production methods face growing constraints. Innovations that improve efficiency and scalability at the process level are therefore essential.

By integrating transcriptional control with impurity reduction, the co-tethered platform exemplifies this shift. It suggests that rethinking the organization of molecular processes can unlock new levels of performance.

Limitations And Future Considerations

While promising, the co-tethered transcription approach is not without limitations.

One key challenge is scalability. Maintaining consistent tethering interactions at large volumes may require new reactor designs or process controls. Variability in component attachment or distribution could impact performance.

Another consideration is flexibility. RNA therapeutics encompass a wide range of constructs, including modified nucleotides and complex secondary structures. The system must demonstrate compatibility across diverse sequence types.

Regulatory considerations also play a role. Any new manufacturing method must meet stringent standards for reproducibility, purity, and safety. Extensive validation will be required to demonstrate equivalence or superiority to existing approaches.

These challenges underscore the need for continued development and evaluation as the technology moves toward practical implementation.

Conclusion

The development of a co-tethered transcription platform represents a meaningful advance in mRNA synthesis. By reorganizing the spatial dynamics of transcription, this approach addresses longstanding challenges associated with yield, purity, and process efficiency.

Through improved control of transcriptional interactions, the system reduces the formation of dsRNA impurities while enhancing the production of full-length, functional mRNA. These benefits have direct implications for the scalability and cost-effectiveness of RNA therapeutics.

More broadly, this work highlights the importance of process innovation in the evolution of the RNA field. As therapeutic applications expand, advances in manufacturing will play an increasingly central role in enabling their success.

In this context, co-tethered transcription is not simply a refinement of existing methods. It represents a shift toward a more integrated and controlled approach to RNA production — one that aligns with the growing demands of the field.

About The Author:

Ruptanu Banerjee, Ph.D., is a research assistant at the University of Massachusetts Amherst, where he has been involved in various research projects. Banerjee previously worked as a teaching assistant at the same university and held positions at IIT Mandi and the National Chemical Laboratory. Banerjee’s research focuses on building high-purity RNA and functional delivery systems that work effectively in cells. Banerjee’s work has been recognized with the NIH National Research Service Award, while his training bridges RNA synthesis, analytical assay development, chemical biology, and delivery, with a strong record of building new tools rather than relying on commercial kits.